NCT03693612 2024-08-28GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid TumorsGlaxoSmithKlinePhase 1/2 Completed26 enrolled 47 charts
NCT00378482 2024-08-22A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.AstraZenecaPhase 2 Completed37 enrolled 13 charts
NCT01975831 2022-10-12A Phase 1 Study to Evaluate MEDI4736 in Combination With TremelimumabLudwig Institute for Cancer ResearchPhase 1 Completed104 enrolled 23 charts